Trial · NCT03880474
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR). | MVA-NP+M1 Group | Participants with laboratory confirmed influenza using RT-PCR | 35 | Participants | |
| Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR). | Saline Placebo Group | Participants with laboratory confirmed influenza using RT-PCR | 23 | Participants | |
| Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR). | MVA-NP+M1 Group | Participants without laboratory confirmed influenza using RT-PCR | 1042 | Participants | |
| Number and Percentage of Participants With Laboratory Confirmed Influenza Using Reverse Transcription Polymerase Chain Reaction (RT-PCR). | Saline Placebo Group | Participants without laboratory confirmed influenza using RT-PCR | 1052 | Participants | |
| Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary | MVA-NP+M1 Group | Positive ILI Cases | 273 | Participants | |
| Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary | Saline Placebo Group | Positive ILI Cases | 273 | Participants | |
| Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary | MVA-NP+M1 Group | Negative ILI Cases | 804 | Participants | |
| Number and Percentage of Participants With Influenza-like Illness (ILI) as Derived From Daily ILI eDiary | Saline Placebo Group | Negative ILI Cases | 802 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | MVA-NP+M1 Group | Participants with Solicited Local Injection Site Reaction (IRS) - Pain | 292 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | Saline Placebo Group | Participants with Solicited Local Injection Site Reaction (IRS) - Pain | 19 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | MVA-NP+M1 Group | Participants with Solicited Local Injection Site Reaction (IRS) - Induration | 113 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | Saline Placebo Group | Participants with Solicited Local Injection Site Reaction (IRS) - Induration | 4 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | MVA-NP+M1 Group | Participants with Solicited Local Injection Site Reaction (IRS) - Warmth | 205 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | Saline Placebo Group | Participants with Solicited Local Injection Site Reaction (IRS) - Warmth | 18 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | MVA-NP+M1 Group | Participants with Solicited Local Injection Site Reaction (IRS) - Erythema | 198 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | Saline Placebo Group | Participants with Solicited Local Injection Site Reaction (IRS) - Erythema | 15 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | MVA-NP+M1 Group | Participants with Severe, Solicited Local Injection Site Reaction | 12 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | Saline Placebo Group | Participants with Severe, Solicited Local Injection Site Reaction | 1 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | MVA-NP+M1 Group | Participants with Solicited Systemic Reactions - Chills | 61 | Participants | |
| Number and Percentage of Participants With Solicited Local and Systemic Reactogenicity Signs and Symptoms for 7 Days Following Vaccination (and Occurrence of Serious Adverse Events SAEs) | Saline Placebo Group | Participants with Solicited Systemic Reactions - Chills | 18 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03880474/results